ISS Endorses Titan and Conavi Merger Ahead of Shareholder Vote

Institutional Shareholder Services recommends Titan shareholders approve the merger, citing strategic benefits and growth potential.

Titan Medical's proposed merger with Conavi Medical will be voted on by shareholders at the annual meeting on September 30, 2024.
Independent advisory firm ISS recommends shareholders vote in favor of the merger, highlighting its potential to enhance shareholder value.
The merger is expected to improve Titan's balance sheet and benefit from reduced listing requirements on the TSXV.
Conavi Medical will present an overview of its patented Novasight Hybrid™ System at a Titan Q&A session on September 19, 2024.
Titan and Conavi's management teams will address shareholder questions during the Q&A session, providing further details on the merger.